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Rigid fusions of designed helical 
repeat binding proteins efficiently 
protect a binding surface from 
crystal contacts
patrick ernst1, Annemarie Honegger1, floor van der Valk1, christina ewald1,2, peer R. e. Mittl1 
& Andreas plückthun1*
Designed armadillo repeat proteins (dArmRPs) bind extended peptides in a modular way. The consensus 
version recognises alternating arginines and lysines, with one dipeptide per repeat. For generating 
new binding specificities, the rapid and robust analysis by crystallography is key. Yet, we have 
previously found that crystal contacts can strongly influence this analysis, by displacing the peptide and 
potentially distorting the overall geometry of the scaffold. Therefore, we now used protein design to 
minimise these effects and expand the previously described concept of shared helices to rigidly connect 
dArmRPs and designed ankyrin repeat proteins (DARPins), which serve as a crystallisation chaperone. 
To shield the peptide-binding surface from crystal contacts, we rigidly fused two DARPins to the N- 
and C-terminal repeat of the dArmRP and linked the two DARPins by a disulfide bond. In this ring-like 
structure, peptide binding, on the inside of the ring, is very regular and undistorted, highlighting the 
truly modular binding mode. Thus, protein design was utilised to construct a well crystallising scaffold 
that prevents interference from crystal contacts with peptide binding and maintains the equilibrium 
structure of the dArmRp. Rigid DARpin-dArmRps fusions will also be useful when chimeric binding 
proteins with predefined geometries are required.
Designed Armadillo repeat proteins (dArmRPs) bind to elongated peptide sequences and may eventually com-
plement classical detection antibodies (a review on alternative binding scaffolds can be found in ref.1, their use 
in therapeutics is reviewed in ref.2). dArmRPs are based on the helical natural armadillo repeat proteins (nArm-
RPs), an α-solenoid repeat protein family that binds to stretches of unfolded regions of proteins3–5. Over the 
last years, a monomeric and well expressing scaffold has been derived from ArmRPs by protein engineering6–10 
(further reviewed in refs11,12). Stable and regularised repeats have been derived from the more irregular repeats 
of nArmRPs. In these proteins, a varying number of internal repeats, binding the peptide, and capping repeats, 
which shield the hydrophobic core from the aqueous environment, are stacked together to form a superhelical 
repeat protein (Fig. 1a). By stacking the internal repeats, or binding modules, a large concave and solvent-exposed 
binding surface is formed (Fig. 1a). Ideally, different modules, each recognising two side-chains of the peptide 
target, would be recombined to bind to arbitrary peptide sequences. These binding modules are obtained by 
preselection from libraries and/or protein design. In principle, these modules could be reassembled in any desired 
arrangement to bind new targets, thereby making costly individual selections against new targets unnecessary.
So far, modules binding to arginine- and lysine-rich peptides have been designed and the development of 
new binding pockets and modules is under way, both by selection techniques and by computational design 
methods (unpublished data). A key analysis technique for the design process is macromolecular crystallography, 
and numerous crystal structures have confirmed the sequence-specific binding of dArmRP to different target 
peptides10,13–16.
However, it soon became clear that crystal forces can have a large impact on the outcome and interpreta-
tion of experimental crystal structures13,14,16. By analysing 27 crystal structures of dArmRPs without peptide or 
in complex with their cognate target peptides, we found that, depending on the crystallisation conditions and 
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crystal packing, the curvature of the superhelix, and consequently the peptide binding mode differed16. Moreover, 
we observed that in some crystals, peptide binding was no longer possible, since the specific packing did not 
sterically allow a peptide to be bound to the dArmRP, i.e., the formed crystal contacts displaced the peptide, 
despite its low nanomolar KD. Like other α-solenoid repeat proteins, dArmRPs frequently crystallise in a tubular 
arrangement. The packing of these tubules contributes to the curvature of the dArmRP, but the exact mode and 
magnitude of this effect remained to be clarified. Several other artefacts, like one peptide binding to more than 
one dArmRP in the crystal or register shifts of bound repetitive peptides have also been observed. In all of these 
cases, the intramolecular crystal packing on which crystallography relies disturbs or interferes with the desired 
molecular features. Since reproducible access to high resolution crystal structures is essential in developing the 
modular binder technology, we set out to solve this problem.
To validate our previous structures and to answer the question of the influence of the crystal lattice, we 
designed a crystallisation construct in which the influence of packing forces on the scaffold should be reduced. 
Ideally, the binding surface would be shielded to exclude any interactions other than the peptide binding to the 
dArmRP. For this purpose, we were aiming at generating a crystal structure with the longest so far crystallised 
continuous peptide binding surface and its cognate binding peptide, namely a dArmRP with six internal repeats 
binding the decapeptide (KR)5. Nearly all of the previously generated structures are dArmRPs with the same 
internal binding module but different repetitions and the six-repeat version would give us the most insight into 
continuous peptide binding.
Designed ankyrin repeat proteins (DARPins) are another class of helical repeat proteins which have been engi-
neered as an alternative binding scaffold17,18. They are well expressing, thermostable and rigid, which is why they 
have been used as binding proteins in many different applications (reviewed in ref.19). In contrast to dArmRPs, 
DARPins preferentially bind to folded domains and carry a β-turn between helices that makes them very rigid. 
To broaden the scope of application for DARPins, they have already been extended in a rigid way by another 
Figure 1. dArmRPs and DARPin-dArmRP fusions. (a) Crystal structure of a dArmRP with five internal 
repeats (orange), binding to a (KR)5 peptide (green) (PDB ID: 5AEI). The hydrophobic core is shielded by two 
capping repeats at the termini (yellow) from the aqueous environment. (b) Structure of a dArmRP repeat with 
helix H1 in orange, helix H2 in pale yellow and helix H3 in red. (c) Model of N-terminal DARPin-dArmRP 
fusions. The three different helices (H1, H2 or H3) of the dArmRP (orange) can be used to construct rigid 
DARPin fusions. Each of the fusions can be constructed with varying length of the helix, leading to a rotation 
of the fused DARPin around the shared helix as a function of helix length. The N-terminal capping repeat of the 
dArmRP is omitted in each case, as the shared helix is part of the first internal repeat. Three examples are shown 
with a fusion to helix one in teal, a fusion to helix two in light green and a fusion to helix three in pale yellow.
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fusion protein to provide additional crystal contacts. To achieve such fusions, the concept of rigid “shared helix” 
fusions of DARPins to other globular proteins or other DARPins was developed to facilitate crystallography of 
DARPin-target complexes20,21. The fused protein is connected to either the N- or C-terminal helix of the DARPin 
and provides an additional surface that can form crystal contacts. In the context of this work, it was observed 
that a specific DARPin, called D12, was particularly successful in providing conserved crystal contacts via its 
hydrophobic binding surface21. The fusion of D12 as a crystallisation chaperone has so far led to numerous crystal 
structures21,22.
Here we show how we applied rigid shared helix fusions and the well crystallising DARPin D12 to construct 
a crystallisation scaffold that exhibits ideal peptide binding on a dArmRP binding surface without interfering 
crystal contacts. Our designs are the first rigid fusions of two binding proteins with completely different binding 
modes. This work did not only answer questions regarding the design of dArmRP peptide binding surfaces but 
also demonstrates new possibilities for the construction of fusions of different types of binding proteins with a 
predictable orientation of the paratopes.
Results
Design of n-terminal DARpin-Armadillo fusion proteins. Shared helices between DARPins can be 
constructed by fusing DARPins at either the N- or C-terminal helix of the capping repeats. When this concept is 
expanded to dArmRPs, the potential number of fusion constructs increases, since one dArmRP module consists 
of three helices (H1, H2 and H3) and each helix can be used to create a shared helix fusion of variable length 
(Fig. 1b,c, SI Fig. 1). To validate that DARPin-dArmRP fusions can be generated as easily as DARPin-DARPin 
fusions, we constructed different fusions, initially concentrating on the construction of N-terminal fusions to 
limit the number of fusions to be tested. We fused the C-terminal helix of the DARPin C-cap to a helix (H1, H2 
or H3) of the first internal repeat of the dArmRP, omitting the dArmRP N-cap. As a fusion partner we chose 
DARPin D12, which has been identified as a crystallisation chaperone, because of its ability to form many differ-
ent sets of crystal contacts21. For this purpose, shared helices with varying length of 1–18 AA were designed in 
silico using the Rosetta protein design suite, as described in ref.21 and tested for clashes between the fused DARPin 
and dArmRP21,23. All shared helix designs that resulted in a direct clash between the DARPin and the dArmRP 
were excluded. Furthermore, the conserved crystal contacts that can be formed by DARPin D12 were taken into 
account with the intention to maintain them when constructing the fusions. To ensure reliable crystallisation we 
excluded shared helix designs in which the known contacts between the DARPin D12 paratopes would lead to 
clashes with other fusion proteins in the crystal lattice21. Finally, 16 potential fusion designs were identified and 
three constructs, each representing a fusion to one of the three dArmRP helices, were tested in crystallisation 
trials to validate that such fusions between DARPins and dArmRPs can be made.
Crystal structure of a fusion of DARPin D12 to helix 2 of a dArmRP. A fusion of the DARPin to 
H2 of the internal repeat of the dArmRP crystallized readily in space group P21 and diffracted to 1.6 Å with one 
molecule in the asymmetric unit (Fig. 2). The crystal was densely packed with a solvent content of 41%. A crystal 
contact was found between the DARPin paratope and the dArmRP binding surface. The first helix of the DARPin 
(residues 145–148) was unwound and formed a longer loop instead of an α-helix. This was probably caused 
by both the crystal contact and its resulting forces as well as by an altered interface between the shared helix 
and the DARPin. Tyr150 pointed towards the interface and made key hydrophobic interactions, thus stabilising 
the changed interface, instead of lying on top of the interface as in the designed model (Fig. 2b). On the other 
hand, the interface between the shared helix and the dArmRP aligned well with the design (Fig. 2a). Overall, 
this results in a Cα RMSD of 2.3 Å at the interface between the DARPin and the shared helix (residues 112–168) 
and in a Cα RMSD of 0.6 Å at the interface between the shared helix and the dArmRP (residues 150–208). This 
construct showed that our design strategy was applicable to fusions between dArmRPs and DARPins, however, 
crystal forces have to be taken into account as they can be strong enough to distort the interfaces of the shared 
helix. Although a target peptide was added in 1.5-fold molar excess prior to crystallisation, it was not visible in 
the electron density map. This was probably due to the crystal contact between a symmetry-related DARPin and 
the binding surface of the dArmRP, displacing the peptide. In summary, these results showed that further design 
efforts were required to prevent the blocking of the peptide-binding site by crystal contacts.
Long and freestanding helices can be bent due to crystal forces. As the peptide was not visible 
in the first structure due to crystal contacts on the binding surface displacing the peptide, we constructed a 
new shared helix. This helix was different from the usual shared helix designs. So far, all shared helices were 
constructed such that the helix was stabilised by packing against the hydrophobic core of both fusion partners. 
However, to orient the DARPin above the binding surface of the dArmRP, a long and freestanding shared helix is 
required. Furthermore, we wanted to improve the occupancy and thus the electron density of the peptide bound 
to the dArmRP in the crystal. As we have shown previously16, flexible peptide linkers can provide an effective 
way to ensure peptide binding in the crystal. This resulted in a dArmRP design with six internal repeats, an 
N-terminally fused DARPin D12 and a C-terminally fused (KR)5-peptide.
The construct expressed well and crystallised in space group P21 with two molecules in the asymmetric unit 
(Fig. 3a). The crystals of this rather bulky construct diffracted to 3.3 Å and had a high solvent content of 69%. The 
structure of the fusion showed that the chaperone structure was still suboptimal. The longer helix of one molecule 
in the asymmetric unit was straight (chain A), while the other was bent (chain B) and revealed that further design 
steps had to be undertaken to stabilise the shared helices (Fig. 3b,c). An alignment of residues 149–241 of the 
straight shared helix and the interface to the dArmRP to the design model resulted in a Cα RMSD of 3 Å for chain 
A and 3.9 Å for chain B. Nevertheless, the two molecules in the asymmetric unit showed a shielded binding sur-
face without crystal contacts. Furthermore, electron density for the fused (KR)5-peptide was visible. The limited 
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resolution, probably caused by the high solvent content and possibly imperfect packing due to the flexible shared 
helix, did not allow to reliably model the peptide in this data set. In order to reduce flexibility and further improve 
the construct we decided to fuse a second DARPin to the C-terminus of the dArmRP.
Two fused DARPins at both dArmRP termini effectively shield the binding surface. To rigid-
ify the construct and exclude potential crystal contacts to the binding interface, we constructed an additional 
C-terminal DARPin D12 fusion, again using the shared-helix strategy. The second DARPin was placed such that 
it came into close contact with the first DARPin, thereby creating a ring-like structure, which was further stabi-
lised by a disulfide linker between the N- and C-terminal D12 DARPins (residues 10 and 625). The disulfide bond 
design was entirely based on an in silico model, situating 615 amino acids in between the two cysteine residues, 
since no prior crystal structure of a C-terminal dArmRP-DARPin fusion was available.
The construct could be readily expressed and purified, and crystals grew after 6 days. They belonged to space 
group C2221 with one molecule in the asymmetric unit, and initial phases were obtained by molecular replace-
ment using the designed structure as a search model (Fig. 4a,b). The first DARPin was hardly visible in the elec-
tron density and showed high B-factors, in contrast to the second DARPin, which was fused via a shared interface 
between the DARPin and the dArmRP. Yet, clear electron density was detected for the disulfide bond, which 
confirmed the accuracy of our designs. The overall Cα RMSD of the crystal structure to the design model was 
found to be 4.5 Å (Fig. 4c). The large deviations are a consequence of the elongated shape of the molecule. The 
DARPin domains are shifted in a distance-dependent manner from the dArmRP domain. During the full relax of 
the whole structure, which followed the side-chain mutation step in the fixbb run, the dArmRP domain became 
more compact than usually observed in crystal structures. While the Cα RMSD of the first DARPin and the 
shared helix (residues 7–190) to the design was 2 Å, the Cα RMSD of the second shared helix and the second 
DARPin (residues 485–671) to the design was only 1.7 Å.
With regard to peptide binding, the structure showed that the design process was successful and a fully 
shielded binding surface was obtained. One crystal contact was formed between the shared interface at the 
dArmRP and a symmetry-related shared helix, but no symmetry-related molecule did make a direct contact to 
the binding surface. Clear electron density was visible for the bound (KR)5-peptide, which was shifted by one 
repeat towards the C-terminus of the dArmRP on the repetitive surface (Fig. 4d, SI Fig. 2a). Residues 2–10 of the 
peptide bound very regularly and nearly identically in every binding pocket. Only the first arginine of the pep-
tide did not bind in an ideal fashion due to the register shift. As expected from the design, every second peptide 
bond of the bound peptide was involved in bidentate hydrogen bonds to the conserved asparagine ladder, which 
keeps the peptide in an extended conformation (SI Fig. 2b). Interestingly, the construct crystallised again in a 
tubular arrangement with the rings stacking on top of each other, which would allow soaking of the target peptide 
(Fig. 5a,b).
Figure 2. Comparison of model (grey) and crystal structure (red) of the fusion to helix 2 of the dArmRP. (a) 
Superposition of model (grey) and crystal structure (red, 1.6 Å resolution) of an N-terminal DARPin-dArmRP 
fusion. N- and C-termini of the proteins are marked. The fusion of DARPin D12 was made to H3 of a dArmRP 
with four internal repeats, with a shared helix length of 5 amino acids. The close-up view shows the distortion 
of the first helix of the DARPin. (b) Detailed view of the changed interface between model and experimental 
structure. The left picture is showing the model, the right one the structure in which Tyr150 inserts into the 
interface between the shared helix and the DARPin.
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Shielded construct displays comparable curvature to previous structures. Our previous analysis 
of 27 dArmRP structures revealed that the curvature of dArmRPs is crucial for peptide binding16. The curvature, 
or supercoiling, can be defined by the distance and angles between two consecutive repeats16. As the peptide is 
bound in an extended conformation over the binding surface, the curvature has to match the backbone distance 
between peptide residues to allow for modular binding. With a maximal distance of 6.7–7 Å between the Cα 
atoms of the first amino acid and the (P + 2) amino acid in a stretched beta-strand conformation, the distance 
between two repeats also has to be in this range16. We concluded that the shielded construct exhibits an optimal 
curvature, since the binding of the (KR)5 peptide to the dArmRP was fully canonical and regular over the whole 
structure and extremely similar in each repeat. Table 1 shows the inter-repeat distances of the construct described 
here. Except for the first repeat, which was influenced by the above-mentioned crystal contact, the distances are 
close to the optimum and match the distances of previous structures that also showed an ideal peptide binding16. 
This also shows that ring formation did not disturb the structure, but on the contrary prevented its deformation 
by crystal contacts.
Discussion
dArmRPs are currently being developed as modular peptide binders11,12. To achieve this goal, a variable number 
of internal repeats, or binding modules, with different binding specificities have to be stacked on top of each other 
to bind to arbitrary peptide sequences. In principle, any binder can be constructed from a subset of modules that 
have been selected beforehand for amino acid specificity. As soon as modules for most amino acids are available, 
there would be no need for any individual selection against the target peptide sequence to be bound.
For the development of this technology, a rapid feedback of both the binding performance and a verification 
of the exact binding mode and interaction with the pockets for the different side chains is required to guide the 
engineering and selection of the modules. Therefore, the analysis of developed modules is very critical, both for 
their binding properties and for the exact structural interactions of the peptide side chains with the pockets, and 
this will have to rely to a large extent on X-ray crystallography.
An analysis of 27 previously obtained dArmRP structures, most of them in complex with their target pep-
tide, showed that crystal contacts can have a major impact on the binding of the peptide and the curvature 
of the dArmRP16. To achieve a reliable structural analysis feedback of different dArmRPs, we had to design 
Figure 3. Crystal structure of the second generation construct with a longer shared helix at 3.3 Å. N- and 
C-termini of the proteins are marked. (a) Asymmetric unit with the DARPin in blue, the shared helix in red, 
the dArmRP in orange and the peptide in green. (b) Overlay of the two molecules of the asymmetric unit, one 
shared helix is bent due to crystal forces; chain A in green, chain B in yellow-orange. (c) Overlay of the designed 
model in grey with the crystal structure in red (chain A, residues 149–214 were used for the alignment).
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constructs, which minimize the effect of crystal contacts on peptide binding or distortion of the dArmRP struc-
ture. Therefore, we wanted to create a crystallisation construct in which the binding surface of the dArmRP is 
fully shielded, thereby eliminating any undesired impact on peptide binding. For this purpose, we adapted the 
concept of rigid shared helices from DARPin-DARPin fusions to fusions between DARPins and dArmRPs21.
In a first round of design we evaluated whether rigid fusions between the well crystallising DARPin D12 and 
a dArmRP can be constructed in an analogous fashion to previously described DARPin-DARPin fusions21. A 
crystal structure of an N-terminal DARPin fusion to helix two of the internal repeat of a dArmRP was obtained. 
However, crystal contacts led to a distortion of the helical part of residues 145–148 and a different interface 
between the shared helix and the DARPin, involving a flip of Tyr150 into the interface. Distortion of the shared 
helix interfaces and deviations from the ideal design, potentially caused by crystal contacts, is a phenomenon we 
have previously observed in DARPin-DARPin fusions21. It has been shown that the formation of crystal contacts 
is favoured over keeping the intact conformation of the shared helices when DARPin D12, a very strong mediator 
of crystal contacts, is used21. Usually, these crystal contacts are observed between the binding paratopes of the 
DARPin; here we show that also secondary contacts to the dArmRP are strong enough to cause a similar distor-
tion of the shared helices. Moreover, no peptide was visible in this crystal structure due to the crystal contact of 
a symmetry-related DARPin interacting with the binding surface of the dArmRP. In summary, DARPin D12 is 
such a good mediator of crystal contacts that regions within the remainder of the protein can be bent to accom-
modate them.
Because of the influence of the crystal contacts observed in the first construct mentioned above, we con-
structed a new fusion with an extended type of a shared helix. This shared helix was free-standing between the 
fusion partners and thus not involved in any kind of hydrophobic packing to the fused protein. The combination 
of this elongated shared helix with a peptide fusion of the target peptide to the dArmRP yielded the first structure 
of a dArmRP with a fully shielded binding surface. One limitation was that the shared helix was too flexible and 
bent in the structure. Furthermore, the crystal had a high solvent content of 69% and diffracted only to 3.3 Å. The 
electron density showed clear evidence for the presence of the peptide in the structure, although not sufficiently 
well defined at this resolution.
Figure 4. Crystal structure of the ring-like construct showing a fully shielded binding surface at 2.4 Å. N- and 
C-termini of the proteins are marked. (a) Asymmetric unit with the DARPins coloured in light blue (N-terminal 
DARPin) and marine (C-terminal DARPin), the shared helices in red, the dArmRP in orange and the peptide 
in green. (b) Top-view highlighting the shielded binding surface (an overview of the crystal packing is shown 
in Fig. 5). (c) Overlay of the designed model in grey with the crystal structure in red. (d) Close-up view of the 
binding surface showing the regular peptide binding. 2mFo-DFc electron density of the peptide contoured at 1 σ.
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To overcome the limitations of the second construct, we expanded the shared helix approach of an 
N-terminally fused DARPin to additionally fuse a DARPin to the C-terminus of the dArmRP. This construct 
was further rigidified by adding a disulfide linker between the two DARPins. Importantly, this disulfide bond 
was placed entirely based on a computational model of the fusion construct, as there was no crystal structure for 
the C-terminal dArmRP-DARPin fusion available. As expected, this construct produced a ring-like structure, 
where the N- and C-terminal regions of the protein are covalently linked. The crystal structure agreed well with 
the designed model with an overall Cα RMSD of 4.5 Å, with the deviation mainly caused by the first DARPin. The 
N-terminal DARPin exhibited considerable flexibility corresponding to poorly defined electron density, but it 
efficiently shielded the binding surface. Not surprisingly, the flexible DARPin domain was not involved in strong 
Figure 5. Crystal packing of the ring-like constructs. The DARPins are colored in light blue (N-terminal 
DARPin) and marine (C-terminal DARPin), the shared helices in red, the dArmRP in orange and the peptide in 
green. (a) View of the x/y plane, highlighting the tubular arrangement. (b) View in the plane of the z-axis with x 
and y at 45 degrees, highlighting the stacking of the rings forming the tubules.
Repeat-pair Cα(P/P + 2) distance in Å
1–2 7.34
2–3 6.78
3–4 6.32
4–5 6.79
5–6 7.03
Table 1. Curvature parameters of the shielded crystallisation construct.
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crystal contacts. The electron density for the shared helix, on the other hand, was well defined and decreased 
gradually towards the N-terminus of the helix and the DARPin-domain.
The most important goal of our design was to observe peptide binding on the surface of the dArmRP without 
direct crystal contacts in the peptide binding area, which could interfere with binding of the peptide. Even though 
the peptide was shifted by one repeat, peptide binding was observed in a geometrically ideal fashion and found 
to be almost identical in four of five arginine residues and in all lysine pockets, as intended by the design. With 
an inter-repeat distance of 6.3–7.3 Å, the curvature of the dArmRP domain of the construct matched that of the 
most regular dArmRP-peptide complex structures solved so far16, except for the first repeat. There was no direct 
crystal contact to the binding pockets of the first repeat, but between the shared helix of a symmetry-related con-
struct and the shared helix-dArmRP interface. This contact probably induced a lengthened inter-repeat distance 
of 7.34 Å between the first and the second repeat of the dArmRP domain. This small deviation from the ideal 
curvature (6.7–7 Å) is also the most likely cause for the shift of the peptide by one repeat. However, the fact that 
the remaining repeats bound four of the five arginines and that all five lysines were bound ideally confirmed the 
success of the design. The shielded binding surface led to the first dArmRP-peptide structure devoid of direct 
crystal contacts, which could have influenced peptide binding.
We have therefore established that, firstly, rigid fusions of DARPins and dArmRPs are possible and the design 
is as straightforward as for DARPin-DARPin fusions, with a high accuracy of the in silico models. Secondly, the 
validity of previously determined dArmRP structures, in which it was unclear to which extent the crystal contacts 
influenced peptide binding, has been confirmed. Although crystal contacts can have a major influence on peptide 
binding by displacing it, dArmRP scan crystallise on their own, maintaining their ideal equilibrium curvature and 
peptide binding. This finding is important for later design steps, in which new pocket and peptide combinations 
need to be analysed regularly and rapidly by crystallography.
For the design we used the Rosetta framework, because this program suite allows to generate and evalu-
ate thousands of models in silico. Nevertheless, we observed significant deviations between the designs and 
the crystal structure, which is primarily a consequence of the solenoid character of the DARPin and dArmRP 
domains and the fusion strategy. Both DARPins and dArmRPs were initially designed using a consensus sequence 
approach with point mutations on the dArmRP domain to enable the fusion strategy. During the fixbb step in the 
Rosetta framework the side chain packing interactions in the hydrophobic core are slightly underestimated, since 
the main chain coordinates were held constant, which causes larger shifts during the subsequent relax step. Yet, 
we think that a more sophisticated design strategy, involving e.g. backrub minimisation or more rounds of flexible 
and constrained minimisation of the whole construct or parts of it could lead to a better agreement between the 
designs and the crystal structures. But despite all advances in the forcefield, this prediction of deviations will still 
be limited by the crystal forces, which play a huge role in the crystallisation of solenoid repeat proteins, especially 
when they are in such an elongated shape as shown here. Future designs will therefore still have to prove whether 
better minimisation and relaxation can increase the accuracy of the designs, but we are optimistic on that.
Furthermore, we think that the DARPin-dArmRP fusions will be valuable also for further applications 
in which geometrically predictable orientations of the paratopes will be of interest, besides applications in 
crystallography.
As an analogy, rigid DARPin-DARPin fusions were found to be highly useful in determining the conforma-
tion of the oncogenic HER2 receptor on the surface of cells24. In that study, the rigid fusion of a binding and a 
non-binding DARPin was used to exclude certain conformational states of the receptor that are accessible to other 
members of the EGFR family. Similarly, biparatopic DARPins, which are fusions of DARPins recognizing two 
different epitopes on neighbouring receptor molecules, have shown strong apoptosis-inducing effects on cancer 
cells overexpressing HER225 as well as on c-MET26. We propose that also DARPin-dArmRP fusions may be useful 
in this context, as they may connect conformational epitopes (bound by the DARPin) with linear epitopes (bound 
by the dArmRP) in a rigid manner with predictable geometry. Such fusions can now be constructed with a high 
level of precision.
Material and Methods
Shared helix design. Similar to the DARPin-DARPin fusion designs described in ref.21, a shared helix con-
necting the DARPin and dArmRP termini was constructed with PyMol27 and the sequence of the interaction 
interface of the helix and the fusion partner were optimised using the Rosetta protein design suite23 with the fixbb 
module involving a constrained relax run before and a full relax run after the design step. Cα RMSDs between the 
designs and the crystal structures were calculated with the CEAlign plugin of PyMOL, using only the Cα-carbon 
atoms with 0 cycles of refinement.
Cloning, expression and purification. The DNA for the shared helix designs was ordered from Invitrogen 
GeneArt (Thermo Fisher Scientific, Massachusetts, USA) and inserted between the N-terminal DARPin and the 
C-terminal dArmRP by using a KasI and a Bsu36I restriction site. The constructs were cloned into the vector 
p148_3C (ref.14) or pQIq (ref.28) carrying an ampicillin resistance. Both vectors are derivatives of the pQE30 
(Qiagen, Hilden, Germany) vector with a 3C-protease cleavable N-terminal His6 or His10 tag, respectively. E. coli 
BL21-Gold or E. coli XL1-blue cells were made competent and transformed with the respective plasmid. Gene 
expression was achieved in two ways: Either cells were grown to an OD of 0.6–1 in 1 L of 2xYT medium, inocu-
lated with 50 mL preculture, and the expression induced by adding 1 mM IPTG and continued for 4 h at 37 °C; 
or expression was achieved in 1 L autoinduction medium29, which was inoculated with 50 mL preculture, and 
cells were continued to grow for 16 h at 30 °C. Cells were harvested by centrifugation at 5,000 x g for 10–15 min, 
resuspended in lysis and wash buffer (50 mM Tris/HCl pH 8, 500 mM NaCl, 20 mM imidazole) and lysed by son-
ication. To remove cell debris and non-lysed cells, the resuspension was centrifuged at 20,000 × g for 20 min and 
the supernatant loaded on a 5 mL Ni-NTA resin column (Qiagen, Hilden, Germany). The column was washed 
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with 5 column volumes (cv) of washing buffer and protein was eluted using 3 cv lysis buffer supplemented with 
250 mM imidazole. 2% (w/w) 3C protease, stored in 10 mM HEPES/NaOH pH 8, 150 mM NaCl, 1 mM DTT, 
10 mM EDTA, 20% glycerol, was added and the imidazole removed by dialysis at 4 °C overnight against 50 mM 
Tris/HCl pH 8, 300 mM NaCl. To remove the protease and the His-tag, the dialysed elution fraction was loaded 
again on a 5 mL Ni-NTA resin column and the flow-through was collected and concentrated to 3–5 mL using 
Amicon centrifugal concentrators (30,000 MWCO, Merck Millipore, Massachusetts, USA). The concentrated 
protein was loaded on a Superdex S75 or S200 column (GE Life Sciences, Little Chalfont, Buckinghamshire, UK). 
Protein was eluted using 10 mM Tris/HCl pH 8, 100 mM NaCl at a flow-rate of 1 mL/min.
Crystallisation and structure determination. Proteins were concentrated to 20 mg/mL with an Amicon 
centrifugal concentrator (30,000 MWCO, Merck Millipore, Massachusetts, USA) and set up for crystallisation. 
For the constructs without a peptide fusion a 2-fold molar excess of (KR)5 peptide was added prior to crystal-
lisation. Suitable crystallisation conditions were screened with 96-well sparse matrix screens at 4 °C (Hampton 
Research, California, USA and Molecular Dimensions (Anatrace, Ohio, USA)). For each condition, three differ-
ent mother liquor to protein ratios were used (1:1, 2:1, 3:1 or 5:1) in 300–400 nL drops, equilibrated against 75 µL 
of reservoir solution. Initial hits were fine-screened using a vertical pH and a horizontal precipitant gradient.
Crystals were flash-frozen in liquid nitrogen after incubation for 10 s in mother liquor supplemented with 20% 
ethylene glycol. For data collection, crystals were taken to beamlines X06DA or X06SA (Paul Scherrer Institute, 
Villigen, Switzerland) equipped with an Eiger 16 M detector or a Pilatus 2 M detector (Dectris, Baden-Wättwil, 
Switzerland) and data were collected at a wavelength of 1 Å. Crystallisation conditions and data collection 
and refinement statistics are summarized in SI Table 1. Data processing was done using XDS, XSCALE and 
XDSCONV30. Molecular replacement was used to solve the phases using PHASER31 and model building was car-
ried out in Coot32. Refinement was done using REFMAC533, PHENIX refine34 and BUSTER35. For determining 
the final resolution of the datasets, paired refinement was done in pdb_redo36 based on ref.37.
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